XERF Skin Tightening: What Does the Clinical Evidence Actually Show?

Non-surgical skin tightening has become increasingly popular, with new devices promising firmer skin, improved facial contours and visible lifting without surgery. One of the latest treatments attracting attention is XERF, a dual frequency monopolar radiofrequency device being promoted for facial rejuvenation.

There has been considerable discussion around XERF, particularly regarding how effective it is, how long the results last and whether it offers advantages over existing radiofrequency treatments.

As a doctor working in aesthetic medicine, I think these are important questions. I'm not against new technologies, and I certainly don't believe that every new treatment needs decades of research before it can be considered useful. However, I do believe the claims being made should reflect the strength of the clinical evidence available.

There is a difference between a treatment having a sound scientific basis, showing promising early results and having robust evidence demonstrating its long-term effectiveness.

How Does XERF Work?

XERF uses two radiofrequency frequencies, 6.78 MHz and 2 MHz, designed to deliver controlled heat into different layers of tissue. The aim is to stimulate collagen contraction and remodelling, potentially improving skin firmness and laxity over time.

Radiofrequency itself is not new. Treatments such as Thermage have been used for many years, and there is an established body of research investigating monopolar radiofrequency for skin tightening.

This is an important point because the underlying science of radiofrequency is not really in question. We know that controlled thermal energy can influence collagen and produce changes within the skin.

However, XERF is a different device with its own energy delivery system, treatment protocols and tissue-heating characteristics. Although research on older devices helps explain why XERF might work, it cannot automatically tell us how effective XERF is, how long its results will last or whether it carries the same risk profile.

Those questions need to be answered through studies specifically investigating XERF.

What Does the Human Clinical Evidence Show?

When reviewing the published literature, one of the first things I look at is how many patients have actually been studied and how long they have been followed.

The available XERF-specific human evidence is still relatively small. Three published clinical studies that can be clearly identified involve 75 patients in total.

A Korean study published by Hwang in 2025 included 20 women aged between 28 and 63. Participants underwent one treatment, with their results assessed after 12 weeks. The study reported improvements in facial appearance, positive patient satisfaction and no unexpected adverse events.

A larger prospective multicentre study published by Weiss and colleagues in 2026 involved 39 participants across four US centres. Patients received two treatments, four weeks apart, with assessments at 30 and 90 days. At the 90-day assessment, approximately 92% were rated by investigators as having achieved aesthetic improvement according to the study's scoring system.

Another study published in 2026 by Erlich and colleagues retrospectively evaluated 16 women following a single XERF treatment. The researchers used three-dimensional imaging, facial measurements and skin-quality assessments, reporting improvements in several parameters, including eyebrow and upper-eyelid position, wrinkles and skin texture over three months.

There are also additional smaller publications and technical reports discussing XERF, including its use around the eyes. These are relevant, although not all provide the same level of clinical outcome evidence.

Taken together, the published findings are encouraging, but the human evidence remains limited in scale. The studies have relatively small patient populations, short follow-up periods and, importantly, the principal clinical studies discussed above did not include randomised control groups.

This doesn't mean the results are meaningless. It simply means we need to be careful about the conclusions we draw from them.

The Problem With Short-Term Follow-Up

For me, one of the biggest unanswered questions is how long the results actually last.

Most of the published XERF-specific human clinical data currently extends to approximately three months. Yet when patients are considering these treatments, they are often interested in improvements lasting six months, a year or potentially longer.

We frequently hear discussions about radiofrequency treatments lasting 12 to 24 months. There may be evidence supporting longer-term improvements with certain established radiofrequency devices, but that doesn't mean we can automatically apply those timelines to XERF.

If a device has only been studied for three months, we cannot confidently say that its results will last a year simply because another device using a similar form of energy has demonstrated longer-lasting effects.

Equally, a three-month follow-up does not mean that the results disappear after three months. It means we do not yet have sufficiently robust XERF-specific published evidence to establish their longer-term durability.

That distinction matters, particularly when patients are investing significant amounts of money in treatment.

What About the Animal Studies?

Some of the research supporting XERF involves preclinical studies conducted using porcine tissue, including young pigs. These studies examine how radiofrequency energy affects different tissue layers and whether changes occur in collagen, elastin and other structures.

This type of research is useful and forms an important part of developing new medical technologies. It helps researchers understand tissue heating, energy distribution and the biological changes that may occur following treatment.

However, demonstrating collagen remodelling in animal tissue is not the same as demonstrating a meaningful and sustained lifting effect in a human face.

Animal studies cannot tell us how noticeable a result will be to a patient, how long it will last or how consistently it will occur across different ages, facial anatomies and degrees of skin laxity.

They help establish the scientific rationale for a treatment, but they do not replace well-designed human clinical trials.

Does XERF Actually Lift the Face?

Another area where I think we need to be careful is the language used around lifting. There is a difference between improving skin firmness, reducing mild laxity and physically repositioning deeper facial tissues.

These outcomes are often grouped together in aesthetic marketing, but they are not interchangeable. Some XERF research has reported measurable changes in eyebrow and upper-eyelid position, as well as changes in facial volume distribution. These are interesting findings, particularly where objective imaging has been used.

However, we need to consider the magnitude of those changes and whether they translate into clinically meaningful improvements for patients. A small measurable improvement is still an improvement, but it should not necessarily be described in the same terms as a surgical lifting procedure.

I think this is particularly important when treating patients with moderate or more advanced facial laxity. Non-surgical devices may offer worthwhile improvements in selected patients, but they cannot be expected to reproduce the results of surgery.

Realistic expectations are essential.

What About Safety and the Risk of Facial Fat Loss?

One of the concerns sometimes raised with energy-based skin-tightening treatments is the possibility of unwanted changes to facial fat.

XERF incorporates features intended to improve energy delivery and treatment control, including temperature monitoring. These developments may offer advantages over previous generations of technology.

However, there is a difference between designing a device to reduce a particular risk and demonstrating through sufficiently large, long-term clinical studies that the risk has been eliminated.

The published XERF human studies have generally reported favourable short-term safety findings, which is reassuring. But relatively small studies with limited follow-up cannot reliably identify uncommon complications or establish long-term safety across a broad patient population.

This does not mean XERF causes facial fat loss, nor does it mean that the device is unsafe. It simply means that claims suggesting such risks have been completely addressed should be supported by appropriate clinical evidence.

In my view, this is an area where further independent research would be particularly valuable.

Why the Evidence From Thermage Isn't Enough

A common argument in discussions about XERF is that monopolar radiofrequency has been studied for years, so we already understand its effectiveness and safety.

There is some truth to this. The existing research on monopolar radiofrequency provides an important foundation, and it would be unreasonable to disregard that evidence entirely.

However, devices are not clinically interchangeable simply because they use the same general technology.

Different devices can vary in frequency, energy delivery, treatment depth, cooling mechanisms, temperature monitoring and treatment protocols. These differences may influence both clinical outcomes and adverse effects.

The fact that Thermage has an established history does not automatically demonstrate that XERF will produce the same degree of improvement, the same longevity or a superior safety profile.

Those are XERF-specific claims, and ideally they should be supported by XERF-specific clinical evidence.

My View on XERF

I think XERF is an interesting technology, and the early clinical findings are encouraging. There is a reasonable scientific basis for how it works, and the published studies suggest it may improve skin firmness, facial appearance and certain measures of skin quality.

My concern isn't necessarily with the technology itself. It is with how confidently some of the claims surrounding it are being presented when the human clinical evidence is still developing.

As doctors, we should be able to acknowledge the potential of a treatment while also recognising the limitations of the research.

We need larger studies, ideally with control groups, objective measurements and longer follow-up. It would also be valuable to see independent research comparing XERF directly with established radiofrequency devices rather than relying on comparisons between separate studies.

Patients deserve to know what has actually been demonstrated, what remains uncertain and what they can realistically expect from a treatment.

So, Is XERF Worth It?

For patients with mild skin laxity who understand the limitations of non-surgical skin tightening, XERF may be a reasonable option to consider following an appropriate medical assessment.

The early results are promising, but we still need stronger evidence to understand how consistent those results are, how long they last and whether XERF offers meaningful advantages over existing technologies.

I don't think we should dismiss new treatments simply because the research is still developing. Innovation is important, and every established technology was new at some point.

But equally, we shouldn't confuse promising preliminary findings with established long term clinical evidence.

Ultimately, my position is straightforward. I'm not against XERF, and I'm not questioning the science of radiofrequency. I simply believe that the claims made about any aesthetic treatment should be proportionate to the evidence supporting that particular device.

That is the standard I believe patients should expect from evidence based aesthetic medicine.

Clinical References

1. Hwang JK. Evaluation of the clinical safety and efficacy of a noninvasive dual-frequency monopolar radiofrequency device in the treatment of facial photoaging sequelae in Republic of Korea: a clinical study. Medical Lasers. 2025;14(1):23–30. https://doi.org/10.25289/ML.24.035

2. Weiss RA, Wang J, DiBernardo B, Bhatia AC. Clinical Outcomes Following Dual-Frequency Noninvasive Monopolar Radiofrequency Treatment for Facial Laxity and Lower Face Lifting: A Prospective Multicenter Study. Cureus. 2026;18(3). https://doi.org/10.7759/cureus.104546

3. Erlich G, Dahan E, Wolf Y. Objective and subjective retrospective evaluation of XERF, a novel single-shot dual-frequency non-invasive monopolar radiofrequency. Lasers in Medical Science. 2026;41:194. https://doi.org/10.1007/s10103-026-04996-0

4. Erlich G, Dahan E, Skorochod R, Wolf Y. Dual-Frequency Non-invasive Monopolar Radiofrequency for Periorbital Tightening: Introduction of Novel Small Treatment Tips. Cureus. 2026;18(1). https://doi.org/10.7759/cureus.101187

This article reflects a review of selected published evidence available as of October 2026 and is intended for educational purposes. It is not a systematic review or a substitute for an individual medical consultation.